| Characteristic . | XELOX (n = 6) . | XELOX plus bevacizumab (n = 58) . | ||
|---|---|---|---|---|
| . | No. of patients . | % . | No. of patients . | % . |
| Sex | ||||
| Male | 5 | 83 | 40 | 69 |
| Female | 1 | 17 | 18 | 31 |
| Age | ||||
| Median | 58.5 | 57.0 | ||
| Range | 40–68 | 33–74 | ||
| ECOG performance status | ||||
| 0 | 6 | 100 | 50 | 86 |
| 1 | 0 | 0 | 8 | 14 |
| Primary tumor site | ||||
| Colon | 4 | 67 | 31 | 53 |
| Rectum | 2 | 33 | 27 | 47 |
| Metastatic site | ||||
| Liver | 5 | 83 | 45 | 78 |
| Lung | 2 | 33 | 28 | 48 |
| Lymph node | 0 | 0 | 27 | 47 |
| Other | 3 | 50 | 5 | 9 |
| No. of organs involved | ||||
| 1 | 2 | 33 | 25 | 43 |
| 2 | 4 | 67 | 21 | 36 |
| 3 | 0 | 0 | 10 | 17 |
| >3 | 0 | 0 | 2 | 3 |
| Adjuvant therapy | ||||
| Yes | 1 | 17 | 8 | 14 |
| No | 5 | 83 | 50 | 86 |
| Characteristic . | XELOX (n = 6) . | XELOX plus bevacizumab (n = 58) . | ||
|---|---|---|---|---|
| . | No. of patients . | % . | No. of patients . | % . |
| Sex | ||||
| Male | 5 | 83 | 40 | 69 |
| Female | 1 | 17 | 18 | 31 |
| Age | ||||
| Median | 58.5 | 57.0 | ||
| Range | 40–68 | 33–74 | ||
| ECOG performance status | ||||
| 0 | 6 | 100 | 50 | 86 |
| 1 | 0 | 0 | 8 | 14 |
| Primary tumor site | ||||
| Colon | 4 | 67 | 31 | 53 |
| Rectum | 2 | 33 | 27 | 47 |
| Metastatic site | ||||
| Liver | 5 | 83 | 45 | 78 |
| Lung | 2 | 33 | 28 | 48 |
| Lymph node | 0 | 0 | 27 | 47 |
| Other | 3 | 50 | 5 | 9 |
| No. of organs involved | ||||
| 1 | 2 | 33 | 25 | 43 |
| 2 | 4 | 67 | 21 | 36 |
| 3 | 0 | 0 | 10 | 17 |
| >3 | 0 | 0 | 2 | 3 |
| Adjuvant therapy | ||||
| Yes | 1 | 17 | 8 | 14 |
| No | 5 | 83 | 50 | 86 |
ECOG, Eastern Cooperative Oncology Group.
| Characteristic . | XELOX (n = 6) . | XELOX plus bevacizumab (n = 58) . | ||
|---|---|---|---|---|
| . | No. of patients . | % . | No. of patients . | % . |
| Sex | ||||
| Male | 5 | 83 | 40 | 69 |
| Female | 1 | 17 | 18 | 31 |
| Age | ||||
| Median | 58.5 | 57.0 | ||
| Range | 40–68 | 33–74 | ||
| ECOG performance status | ||||
| 0 | 6 | 100 | 50 | 86 |
| 1 | 0 | 0 | 8 | 14 |
| Primary tumor site | ||||
| Colon | 4 | 67 | 31 | 53 |
| Rectum | 2 | 33 | 27 | 47 |
| Metastatic site | ||||
| Liver | 5 | 83 | 45 | 78 |
| Lung | 2 | 33 | 28 | 48 |
| Lymph node | 0 | 0 | 27 | 47 |
| Other | 3 | 50 | 5 | 9 |
| No. of organs involved | ||||
| 1 | 2 | 33 | 25 | 43 |
| 2 | 4 | 67 | 21 | 36 |
| 3 | 0 | 0 | 10 | 17 |
| >3 | 0 | 0 | 2 | 3 |
| Adjuvant therapy | ||||
| Yes | 1 | 17 | 8 | 14 |
| No | 5 | 83 | 50 | 86 |
| Characteristic . | XELOX (n = 6) . | XELOX plus bevacizumab (n = 58) . | ||
|---|---|---|---|---|
| . | No. of patients . | % . | No. of patients . | % . |
| Sex | ||||
| Male | 5 | 83 | 40 | 69 |
| Female | 1 | 17 | 18 | 31 |
| Age | ||||
| Median | 58.5 | 57.0 | ||
| Range | 40–68 | 33–74 | ||
| ECOG performance status | ||||
| 0 | 6 | 100 | 50 | 86 |
| 1 | 0 | 0 | 8 | 14 |
| Primary tumor site | ||||
| Colon | 4 | 67 | 31 | 53 |
| Rectum | 2 | 33 | 27 | 47 |
| Metastatic site | ||||
| Liver | 5 | 83 | 45 | 78 |
| Lung | 2 | 33 | 28 | 48 |
| Lymph node | 0 | 0 | 27 | 47 |
| Other | 3 | 50 | 5 | 9 |
| No. of organs involved | ||||
| 1 | 2 | 33 | 25 | 43 |
| 2 | 4 | 67 | 21 | 36 |
| 3 | 0 | 0 | 10 | 17 |
| >3 | 0 | 0 | 2 | 3 |
| Adjuvant therapy | ||||
| Yes | 1 | 17 | 8 | 14 |
| No | 5 | 83 | 50 | 86 |
ECOG, Eastern Cooperative Oncology Group.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
